Randomized, single-dose, open-label, two-part, two-period, cross-over study to compare the pharmacokinetics, safety and tolerability of the pediatric and adult formulation of branaplam and to investigate the adult formulation in fed and fasted state in healthy participants

ovartis (Switzerland)0 个研究点目标入组 32 人开始时间: 2022年4月8日最近更新: 2022年10月31日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 32

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

性别: All

入选标准

•1. Healthy male and non-childbearing potential female participants, 18 to 60 years of age inclusive, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening and baseline 1.
•2. Participants must weigh at least 50 kg at screening to participate in the study, and must have a body mass index within the range of 18.0 to 30.0 kg/m² as measured at screening. Body mass index = body weight (kg) / [height (m)]².
•3. At screening and baseline vital signs (systolic blood pressure, diastolic blood pressure and pulse rate) will be assessed in the supine position and again in the standing position (after at least 3 minutes in each position). Oral body temperature will also be taken with the other supine vital sign assessments. Supine vital signs must be within the following ranges at screening and baseline 1:
•3.1. Oral body temperature 35.0-37.5°C (inclusive)
•3.2. Systolic blood pressure, 90-139 mmHg (inclusive)
•3.3. Diastolic blood pressure, 50-89 mmHg (inclusive)
•3.4. Pulse rate, 40-90 bpm (inclusive)
•Participants should be excluded if their standing vital signs (relative to supine) show findings which, in the opinion of the Investigator, are associated with clinical manifestation of postural hypotension (i.e. absence of any other cause). An Investigator should carefully consider enrolling participants with either a >20 mmHg decrease in systolic blood pressure or a >10 mmHg decrease in diastolic blood pressure accompanied by a >20 bpm increase in pulse rate.

排除标准

•1. Participants who have received any investigational medicinal product in a clinical research study within the 90 days or 5 half-lives, whichever is longer, prior to Period 1 Day 1
•2. Participants who have previously been administered investigational medicinal product in this study. Participants who have taken part in Part 1 are not permitted to take part in Part 2.
•3. Significant illness, which has not resolved within 2 weeks prior to initial dosing
•4. Men planning to father children in the near future (next 6 months)
•5. Male participant who reports having a pregnant or nursing (lactating) partner
•6. Sexually active males unwilling to adhere to the contraception requirements of the study as detailed below:
•6.1. A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of the investigational drug via seminal fluid to their partner
•6.2. Males with partners of childbearing potential must use a condom during intercourse while taking the investigational drug and for 118 days after stopping the investigational drug (duration to cover one spermatogenesis cycle plus 5 half-lives)
•6.3. Additionally, male participants with female partners of childbearing potential should also use another highly effective method of contraception. Highly effective contraception methods include:
•6.3.1. Partner’s bilateral tubal occlusion
•6.3.2. Male participant sterilization (vasectomy; at least 6 months prior to screening)
•6.3.3. Partner’s use of oral (estrogen and progesterone; or progesterone only that inhibits ovulation), injected, or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system, or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example, hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months
•6.3.4. Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
•6.3.5. Males with partners of non-childbearing potential must use a condom during intercourse while taking the investigational drug and for 28 days after stopping the investigational drug (duration to cover 5 half-lives). In addition, male participants should not donate sperm for 118 days after stopping the investigational drug.
•6.4. Women of childbearing potential who report being pregnant or nursing (lactating). Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. Women are considered not of child-bearing potential if they are post-menopausal or have had surgical bilateral salpingectomy or bilateral oophorectomy (with or without hysterectomy) or total hysterectomy at least six weeks before screening. Women are considered post-menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age-appropriate, history of vasomotor symptoms) and serum follicle-stimulating hormone concentration of =40 IU/l. Fol

研究者

发起方

ovartis (Switzerland)

相似试验

尚未招募

4 期

A Single Dose, Randomized, Open-label, Two-treatment, Four-period, Two-sequence, Replicate Crossover Bioequivalence Study of Generic Lercanidipine 20 mg Film-coated Tablets and Reference Product (ZANIDIP) in Healthy Thai Volunteers under Fasting ConditionsHealthy Thai Volunteers

TCTR20230120003International Bio Service48

尚未招募

1 期

A Single Dose, Randomized, Open-label, Two-treatment, Four-period, Two-sequence, Replicate Crossover Bioequivalence Study of Generic Dabigatran Etexilate Capsules 150 mg and Reference Product (Pradaxa) in Healthy Thai Volunteers under Fasting ConditionsBioequivalence Study Healthy Thai VolunteersDabigatran etexilate 150 mg Capsules in Healthy Thai Volunteers

TCTR20230427002International Bio Service Co.,Ltd48

尚未招募

1 期

A Single Dose, Randomized, Open-label, Two-treatment, Four-period, Two-sequence, Replicate Crossover Bioequivalence Study of Generic Racecadotril 100 mg Capsules and Reference Product (HIDRASEC) in Healthy Thai Volunteers under Fasting ConditionsHealthy Thai Volunteers

TCTR20240604001International Bio Service44

已完成

不适用

A Bioequivalence Study of Capecitabine 500 mg with XelodaÂ® 500 mg in Adult Cancer Patients Under Fed Condition.

CTRI/2021/09/036815SP Accure Labs Pvt Ltd33

已完成

Unknown

An single dose, two-treatment, two-way crossover study of study product containing glutathione, in healthy, adult, human subjects under fasting conditions.

CTRI/2023/08/056674YourZooki holdings Ltd24